Stocktoria
Scilex Holding Co SCLX
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-01-11
Scilex Holding Co financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $30.3M | $56.6M | $46.7M | $38.0M | $31.3M |
| Gross profit | $125.8M | $167.4M | — | — | — |
| R&D expense | $20.7M | $9.6M | $12.7M | $9.1M | $9.2M |
| SG&A expense | $266.9M | $119.0M | $119.6M | $64.9M | $50.6M |
| Operating income | -$346.0M | -$83.4M | -$105.4M | -$50.6M | -$35.8M |
| Interest expense | — | — | $1.1M | $9.6M | $11.8M |
| Income tax | $26,000 | -$1,000 | $13,000 | $4,000 | $5,000 |
| Net income | -$374.1M | -$72.8M | -$114.3M | -$23.4M | -$88.4M |
| EPS (diluted) | $-36.48 | $-8.05 | $-1.28 | $-0.17 | $-0.67 |
| Operating cash flow | $3.8M | $19.3M | -$20.7M | $21.3M | -$28.7M |
| Free cash flow | $3.7M | $19.3M | -$20.7M | $21.3M | -$28.7M |
| Cash & equivalents | $5.0M | $3.3M | $3.9M | $2.2M | $4.3M |
| Inventory | $4.8M | $2.4M | $4.2M | $1.4M | $2.6M |
| Total assets | $365.0M | $93.0M | $101.3M | $86.5M | $77.9M |
| Total liabilities | $576.7M | $285.6M | $274.2M | $50.3M | $301.8M |
| Shareholders' equity | -$211.8M | -$192.6M | -$172.9M | $36.2M | -$223.9M |
Source: SEC EDGAR filings · CIK 0001820190 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.